Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
NCT06465433
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
25
Enrollment
INDUSTRY
Sponsor class
Conditions
Hematologic Malignancies
Interventions
DRUG:
Tafasitamab
Sponsor
Incyte Corporation